Truist Securities analyst Robyn Karnauskas reiterated a Buy rating and $458.00 price target on Biogen (NASDAQ: BIIB) after the FDA ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE